Geneseeq Canada Partners with UHN in Groundbreaking Gene Study for Cancer Research

In a significant advancement for cancer research, Geneseeq Technology Inc. (Geneseeq Canada) has announced a new partnership with the University Health Network (UHN), one of Canada’s premier research hospitals. This collaboration will support various initiatives, most notably the SHERLOCK study, a large-scale research project focused on genomic profiling and molecular monitoring in oncology.

Geneseeq Canada, recognized for its innovative approaches in genomic testing, will play an integral role in the SHERLOCK study (ClinicalTrials.gov NCT07524114). This promising venture at UHN’s prestigious Princess Margaret Cancer Centre—ranked among the world’s top 10 cancer centers—aims to enhance our understanding of cancer through comprehensive genomic analysis.

Over the next five years, the SHERLOCK study seeks to enroll approximately 7,000 patients suffering from various solid tumors and hematologic malignancies. By tracking these patients over time and analyzing both tumor tissue and blood samples, researchers aim to gain insights into how tumors respond to treatment, monitor disease recurrence, and unravel the complexities of cancer evolution. Such knowledge is pivotal in refining treatment protocols and improving patient outcomes.

Geneseeq's role in this collaboration includes providing cutting-edge genomic testing and molecular residual disease (MRD) monitoring services. These efforts will initially support around 1,000 patients involved in the SHERLOCK study. Geneseeq technologies are devised to enhance precision oncology, ultimately tailoring treatments based on specific genomic profiles. For those patients with solid tumors, Geneseeq’s flagship assay, GeneseeqPrime®, will be employed to characterize their cancer’s molecular features through baseline tumor tissue analysis. Moreover, longitudinal blood samples will utilize Shielding® Ultra, a molecular monitoring technology adept at detecting cancer signals with high sensitivity.

For patients with hematological malignancies, the genomic profiling services will include Hemasalus®, designed specifically for cancers of the blood. This dual approach not only contributes to the understanding of each patient's unique cancer characteristics but also aids in detecting any potential signs of recurrence more efficiently.

Dr. Xue Wu, CEO of Geneseeq Canada, expressed enthusiasm for this collaboration, stating, "Canada has played an important role in Geneseeq's journey. We proudly support Canadian-led cancer research through the SHERLOCK program and are honored to be its first commercial genomic testing partner. This partnership reflects our commitment to advancing the scientific understanding of cancer genomics and MRD, ultimately aiming to benefit patients."

Similarly, Dr. Lillian Siu, a clinician and senior scientist at UHN’s Princess Margaret Cancer Centre, highlighted the importance of interdisciplinary collaboration in advancing precision oncology. "One of the biggest challenges in cancer care is accurately determining whether curative treatment has completely eradicated the disease or if it remains to resurface. Our objective with SHERLOCK is to combine genomic analyses and clinical outcomes, enabling us to better understand treatment responses and effectively monitor cancer evolution."

As the SHERLOCK study progresses, it is expected to yield essential evidence regarding the biological and clinical importance of MRD. This potentially transformative research could help reshape future precision oncology strategies, inform clinical trial design, and spark further biomarker research. The ongoing partnership between Geneseeq and UHN underlines a shared commitment to elevating cancer genomics, early detection, and enhanced patient care through innovative research.

About Geneseeq

Geneseeq Technology Inc. is the Canadian arm of the global precision oncology enterprise, Geneseeq, focused on improving cancer detection, diagnosis, and treatment through advanced next-generation sequencing technologies. Headquartered in Ontario, Canada, Geneseeq runs a certified laboratory that promotes cancer genomic research and collaborates with healthcare institutions and clinical partners globally. The company’s broad portfolio includes comprehensive genomic profiling, minimal residual disease monitoring, and multi-cancer early detection solutions, making significant strides toward improving patient care in oncology worldwide.